Stock Events

Insulet 

€206.3
61
+€2.1+1.03% Wednesday 19:55

Statistics

Day High
206.3
Day Low
199.6
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
14.22B
P/E Ratio
36.67
Dividend Yield
-
Dividend
-

Upcoming

Earnings

31OctExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
0.11
0.94
1.76
2.59
Expected EPS
0.787798
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GOV.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Tandem Diabetes Care
TNDM
Mkt Cap2.85B
Tandem Diabetes Care, Inc. competes directly with Insulet by offering insulin pump therapy for diabetes management, which is a direct alternative to Insulet's Omnipod system.
Medtronic
MDT
Mkt Cap113.61B
Medtronic plc is a major competitor in the insulin pump market, offering a range of products that compete with Insulet's offerings for diabetes management.
Dexcom
DXCM
Mkt Cap27.79B
DexCom, Inc. provides continuous glucose monitoring (CGM) systems that are often used in conjunction with insulin pumps like those offered by Insulet, making them a competitor in the broader diabetes management space.
Abbott Laboratories
ABT
Mkt Cap197.08B
Abbott Laboratories offers the FreeStyle Libre, a CGM system that competes with the integrated diabetes management solutions provided by Insulet.
Insulet
PODD
Mkt Cap14.22B
Insulet Corporation is listed as its own competitor due to an error. Please disregard this entry.
Senseonics
SENS
Mkt Cap208.39M
Senseonics Holdings, Inc. offers the Eversense CGM system, which competes in the diabetes management market by providing an alternative to the CGM solutions that can be used with Insulet's products.
Novo Nordisk
NVO
Mkt Cap620.4B
Novo Nordisk A/S is a leading provider of insulin and other diabetes care products that, while not a direct competitor in the insulin pump market, competes in the broader diabetes management space.
Sanofi
SNY
Mkt Cap141.43B
Sanofi provides a range of diabetes care solutions, including insulin therapies that compete with the insulin management solutions offered by Insulet.
Mannkind
MNKD
Mkt Cap1.72B
MannKind Corporation offers Afrezza, an inhaled insulin, providing a non-injectable alternative to insulin delivery that competes with traditional pump therapies like those offered by Insulet.

Analyst Ratings

229.38Average Price Target
The highest estimate is €260.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

About

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Show more...
CEO
Dr. James R. Hollingshead Ph.D.
Employees
3000
Country
US
ISIN
US45784P1012
WKN
000A0MQX8

Listings